

PERSONAL INFORMATION

Bernd Gansbacher

WORK EXPERIENCE

January 1996–September 2013

Director emeritus and Professor

Technical University of Munich (Germany)

Ordinarius and Director emeritus, Institut für Experimentelle Onkologie u. Therapieforschung ,
Klinikum rechts der Isar, Technical University of Munich, Germany February 1, 1996-2013

June 1988–January 1996

Associate Professor

Memorial Sloan Kettering Cancer Center (United States)

1. Clinical Assistant, Memorial Sloan Kettering Cancer Center 1988 - 1991.

Clinical Assistant Physician, Leukemia Service, Memorial Hospital for Cancer and Allied Diseases
1988 - 1991.

Instructor, Department of Medicine, Cornell University Medical College 1988 - 1991.

2. Assistant Member, Memorial Sloan Kettering Cancer Center 1992 - 1994.

Assistant Attending Physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center 1992 -
1994.

Assistant Professor, Department of Medicine, Cornell University Medical College 1992 - 1994.

3. Associate Member, Memorial Sloan Kettering Cancer Center, 1994 - 1996.

Associate Attending Physician, Leukemia and Autologous Bone Marrow Transplant Service, Memorial
Sloan-Kettering Cancer Center 1994 - 1996.

Associate Professor, Department of Medicine, Cornell University Medical College 1994 – 1996

EDUCATION AND TRAINING

June 1980–June 1988

**specialty training in Internal Medicine, Allergy/Immunology and
Oncology**

University of Pennsylvania and Memorial Sloan Kettering Cancer Center (United States)

1. Internship, Department of Medicine, Presbyterian University of Pennsylvania Medical Center,
Philadelphia July 1980 - June 1981.

2. Residency, Department of Medicine, Presbyterian University of Pennsylvania Medical Center,
Philadelphia July 1981 - June 1983.

3. Fellowship Allergy / Immunology, Hospital of The University of Pennsylvania, Philadelphia July 1983
- June 1985.

4. Research Associate, Wistar Institute of Anatomy, Laboratory of Dr. Carlo Croce, Philadelphia July
1985 - June 1986.

5. Oncology Fellowship, Memorial Sloan Kettering Cancer Center New York July 1986 - June 1988.

ADDITIONAL INFORMATION

Expertise

Board certified in Internal Medicine

Board certified in Allergy and Immunology

Board certified in Oncology

Gene Therapy

Publications

1. Optimizing adenoviral transduction of endothelial cells under flow conditions. Anton M, Wolf A,
Mykhaylyk O, Koch C, Gansbacher B, Plank C. Pharm Res. 2012 May;29(5):1219-31.

2. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach
to eradicate malignant glioma. Holzmüller R, Mantwill K, Haczek C, Rognoni E, Anton M, Kasajima A,

- Weichert W, Treue D, Lage H, Schuster T, Schlegel J, Gansbacher B, Holm PS. *Int J Cancer*. 2011 Sep 1;129(5):1265-76.
3. Prostate cancer gene therapy: attempts to innovate. Kochanek S, Gansbacher B. *Hum Gene Ther*. 2010 Jul;21(7):791.
4. Tetracycline-regulated bone morphogenetic protein 2 gene expression in lentivirally transduced primary rabbit chondrocytes for treatment of cartilage defects. Wübbenhorst D, Dumler K, Wagner B, Wexel G, Imhoff A, Gansbacher B, Vogt S, Anton M. *Arthritis Rheum*. 2010 Jul;62(7):2037-46.
5. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. Schrötzlmair F, Kopitz C, Halbgewachs B, Lu F, Algül H, Brünner N, Gansbacher B, Krüger A. *J Cell Mol Med*. 2010 Dec;14(12):2760-70.
6. Tissue engineering of the anterior cruciate ligament-sodium dodecyl sulfate cellularized and revitalized tendons are inferior to native tendons. Tischer T, Aryee S, Drexel G, Steinhauser E, Adamczyk C, Eichhorn S, Milz S, Martinek V, Gansbacher B, Imhoff AB, Vogt S. *Tissue Eng Part A*. 2010 Mar;16(3):1031-40.
7. Schrötzlmair F, Kopitz C, Halbgewachs B, Lu F, Algül H, Brünner N, Gansbacher B, Krüger A. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. *J Cell Mol Med*. 2009 Oct 23.
8. Bonini C, Gansbacher B. Cancer gene therapy: present and future. *Cancer gene therapy: present and future*. *Hum Gene Ther*. 2009 Oct;20(10):1100.
9. Tischer T, Aryee S, Wexel G, Steinhauser E, Adamczyk C, Eichhorn S, Milz S, Martinek V, Gansbacher B, Imhoff AB, Vogt S. Tissue Engineering of the ACL - SDS Chemically Acellularized and Revitalized Tendons are Inferior to Native Tendons. *Tissue Eng Part A*. 2009 Oct 21. [Epub ahead of print]
10. Rognoni E, Widmaier M, Haczek C, Mantwill K, Holzmüller R, Gansbacher B, Kolk A, Schuster T, Schmid RM, Saur D, Kaszubiak A, Lage H, Holm PS. Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo. *Cancer Gene Ther*. 2009 Oct;16(10):753-63. Epub 2009 Apr 10.
11. Brill TH, Kübler HR, Pohla H, Buchner A, Fend F, Schuster T, von Randenborgh H, Paul R, Kummer T, Plank C, Eisele B, Breul J, Hartung R, Schendel DJ, Gansbacher B. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. *Hum Gene Ther*. 2009 Dec;20(12):1641-51
12. Higuchi T, Anton M, Dumler K, Seidl S, Pelisek J, Saraste A, Welling A, Hofmann F, Oostendorp RAJ, Gansbacher B, Nekolla SG, Bengel FM, Botnar RM, Schwaiger M. Combined Reporter Gene PET and Iron Oxide MR Imaging for Monitoring Survival and Localization of Transplanted Cells in the Rat Heart. *J Nucl. Med*. 2009 Jul;50(7): 1099-94. Epub 2009 June 12
13. Salzmann GM, Nuemberger B, Schmitz P, Anton M, Stoddart MJ, Grad S, Milz S, Tischer T, Vogt S, Gansbacher B, Imhoff AB, Alini M. Physicobiochemical Synergism Through Gene Therapy and Functional Tissue Engineering for In Vitro Chondrogenesis. *Tissue Eng Part A*. 2009 Mar 12. [Epub ahead of print]
14. Vogt S, Wexel G, Tischer T, Schillinger U, Ueblacker P, Wagner B, Hensler D, Wilisch J, Geis C, Wübbenhorst D, Aigner J, Gerg M, Krüger A, Salzmann GM, Martinek V, Anton M, Plank C, Imhoff AB, Gansbacher B. The influence of the stable expression of BMP2 in fibrin clots on the remodelling and repair of osteochondral defects. *Biomaterials*. 2009 Apr;30(12):2385-92. Epub 2009 Jan 31.
15. Holzbach T, Vlaskou D, Neshkova I, Konerding MA, Wörtler K, Mykhaylyk O, Gansbacher B, Machens HG, Plank C, Giunta RE. Non-viral VEGF gene therapy - Magnetofection of acoustically active magnetic lipospheres ("Magnetobubbles") increases tissue-survival in an oversized skin flap model. *J Cell Mol Med*. 2008 Nov 14. [Epub ahead of print]
16. Holzbach T, Neshkova I, Vlaskou D, Konerding MA, Gansbacher B, Biemer E, Giunta RE. Searching for the right timing of surgical delay: angiogenesis, vascular endothelial growth factor and perfusion changes in a skin-flap model. *J Plast Reconstr Aesthet Surg*. 2008 Sep 22.
17. Kopitz C, Gerg M, Gansbacher B, Krüger A. Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. *Hum Gene Ther*. 2008 Oct;19(10):1039-49.
18. May F, Matiasek K, Vroemen M, Caspers C, Mrva T, Arndt C, Schlenker B, Gais P, Brill T, Buchner A, Blesch A, Hartung R, Stief C, Gansbacher B, Weidner N. GDNF-transduced Schwann cell grafts enhance regeneration of erectile nerves. *Eur Urol*. 2008 Nov;54(5):1179-87. Epub 2008 Feb 15.
19. Vogt S, Ueblacker P, Geis C, Wagner B, Wexel G, Tischer T, Krüger A, Plank C, Anton M, Martinek V, Imhoff AB, Gansbacher B. Efficient and stable gene transfer of growth factors into

- chondrogenic cells and primary articular chondrocytes using a VSV.G pseudotyped retroviral vector. *Biomaterials*. 2008 Mar;29(9):1242-9
20. Bieler A, Mantwill K, Holzmüller R, Jurchott K, Kaszubiak A, Stark S, Glockzin G, Lage H, Grosu AL, Gansbacher B, Holm PS. Impact of radiation therapy on the oncolytic adenovirus dl520: Implications on the treatment of glioblastoma. *Radiother Oncol*. 2008 Mar;86(3):419-27. Epub 2007 Oct 29
21. Wilson JM, Gansbacher B, Berns KI, Bosch F, Kay MA, Naldini L, Wei YQ. Good news on the clinical gene transfer front. *Editorial Human Gene Therapy* 2008; 19:429-430
22. Ueblacker P, Wagner B, Vogt S, Salzmann G, Wexel G, Krüger A, Plank C, Brill T, Specht K, Hennig T, Schilling U, Imhoff AB, Martinek V, Gansbacher B. In vivo analysis of retroviral gene transfer to chondrocytes within collagen scaffolds for the treatment of osteochondral defects. *Biomaterials*. 2007;28(30):4480-7.
23. Brill TH, Kubler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R, Paul R, Schendel DJ, Gansbacher B. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer - a phase I clinical trial. *J Gene Med*. 2007 Jul;9(7):547-60.
24. Martinek V, Ueblacker P, Braun K, Nitschke S, Mannhardt R, Specht K, Gansbacher B, Imhoff AB. Second generation of meniscus transplantation: in-vivo study with tissue engineered meniscus replacement. *Archives of orthopaedic and trauma surgery*. 2006;126(4):228-34.
25. Mantwill K, Kohler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, Surowiak P, Dravits T, Treiber U, Hartung R, Gansbacher B, Holm PS. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. *Cancer research*. 2006;66(14):7195-202.
26. Glockzin G, Mantwill K, Jurchott K, Bernshausen A, Ladhoff A, Royer HD, Gansbacher B, Holm PS. Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development. *Journal of virology*. 2006;80(8):3904-11.
27. Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Kohler-Vargas N, Lage H, Gansbacher B, Holm PS. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. *Human gene therapy*. 2006;17(1):55-70.
28. Miyagawa M, Beyer M, Wagner B, Anton M, Spitzweg C, Gansbacher B, Schwaiger M, Bengel FM. Cardiac reporter gene imaging using the human sodium/iodide symporter gene. *Cardiovascular research*. 2005;65(1):195-202.
29. Miyagawa M, Anton M, Wagner B, Haubner R, Souvatzoglou M, Gansbacher B, Schwaiger M, Bengel FM. Non-invasive imaging of cardiac transgene expression with PET: comparison of the human sodium/iodide symporter gene and HSV1-tk as the reporter gene. *European journal of nuclear medicine and molecular imaging*. 2005;32(9):1108-14.
30. May F, Vroemen M, Matiasek K, Henke J, Brill T, Lehmer A, Apprich M, Erhardt W, Schoeler S, Paul R, Blesch A, Hartung R, Gansbacher B, Weidner N. Nerve replacement strategies for cavernous nerves. *European urology*. 2005;48(3):372-8.
31. May F, Schoeler S, Vroemen M, Matiasek K, Apprich M, Erhardt W, Hartung R, Gansbacher B, Weidner N. [Nerve repair strategies for restoration of erectile function after radical pelvic surgery]. *Der Urologe Ausg*. 2005;44(7):780-4.
32. Kopitz C, Anton M, Gansbacher B, Krüger A. Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. *Cancer research*. 2005;65(19):8608-12.
33. Holzbach T, Taskov C, Neshkova I, Holm PS, Konerding MA, Schams D, Gansbacher B, Biemer E, Giunta RE. [Angiogenesis VEGF165 gene therapy with AdVEGF- a new delay procedure for flaps]. *Handchir Mikrochir Plast Chir*. 2005;37(6):365-74.
34. Holzbach T, Taskov C, Henke J, Busch R, Gansbacher B, Biemer E, Giunta RE. [Evaluation of perfusion in skin flaps by laser-induced indocyanine green fluorescence]. *Handchir Mikrochir Plast Chir*. 2005;37(6):396-402.
35. Giunta RE, Holzbach T, Taskov C, Holm PS, Konerding MA, Schams D, Biemer E, Gansbacher B. AdVEGF165 gene transfer increases survival in overdimensioned skin flaps. *The journal of gene medicine*. 2005;7(3):297-306.
36. Giunta RE, Holzbach T, Taskov C, Holm PS, Brill T, Busch R, Gansbacher B, Biemer E. Prediction of flap necrosis with laser induced indocyanine green fluorescence in a rat model. *British journal of plastic surgery*. 2005;58(5):695-701.

37. Giunta RE, Gansbacher B. [Angiogenesis gene therapy - a new innovation push in plastic surgery?]. *Handchir Mikrochir Plast Chir.* 2005;37(6):363-4.
38. Anton M, Goma IE, von Lukowicz T, Molls M, Gansbacher B, Wurschmidt F. Optimization of radiation controlled gene expression by adenoviral vectors in vitro. *Cancer gene therapy.* 2005;12(7):640-6.
39. Ueblacker P, Wagner B, Kruger A, Vogt S, DeSantis G, Kennerknecht E, Brill T, Hillemanns M, Salzmann GM, Imhoff AB, Plank C, Gansbacher B, Martinek V. Inducible nonviral gene expression in the treatment of osteochondral defects. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society.* 2004;12(9):711-9.
40. Miyagawa M, Anton M, Haubner R, Simoes MV, Stadele C, Erhardt W, Reder S, Lehner T, Wagner B, Noll S, Noll B, Grote M, Gambhir SS, Gansbacher B, Schwaiger M, Bengel FM. PET of cardiac transgene expression: comparison of 2 approaches based on herpesviral thymidine kinase reporter gene. *J Nucl Med.* 2004;45(11):1917-23.
41. May F, Weidner N, Matiasek K, Vroemen M, Mrva T, Caspers C, Henke J, Brill T, Lehmer A, Blesch A, Erhardt W, Gansbacher B, Hartung R. [Tissue engineering of erectile nerves]. *Der Urologe Ausg.* 2004;43(10):1242-8.
42. May F, Weidner N, Matiasek K, Caspers C, Mrva T, Vroemen M, Henke J, Lehmer A, Schwaibold H, Erhardt W, Gansbacher B, Hartung R. Schwann cell seeded guidance tubes restore erectile function after ablation of cavernous nerves in rats. *The Journal of urology.* 2004;172(1):374-7.
43. Holm PS, Lage H, Bergmann S, Jurchott K, Glockzin G, Bernshausen A, Mantwill K, Ladhoff A, Wichert A, Mymryk JS, Ritter T, Dietel M, Gansbacher B, Royer HD. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. *Cancer research.* 2004;64(1):322-8.
44. Elezkurtaj S, Kopitz C, Baker AH, Perez-Canto A, Arlt MJ, Khokha R, Gansbacher B, Anton M, Brand K, Kruger A. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. *The journal of gene medicine.* 2004;6(11):1228-37.
45. Anton M, Wittermann C, Haubner R, Simoes M, Reder S, Essien B, Wagner B, Henke J, Erhardt W, Noll S, Hackett NR, Crystal RG, Schwaiger M, Gansbacher B, Bengel FM. Coexpression of herpesviral thymidine kinase reporter gene and VEGF gene for noninvasive monitoring of therapeutic gene transfer: an in vitro evaluation. *J Nucl Med.* 2004;45(10):1743-6.
46. Anton M, Wagner B, Haubner R, Bodenstern C, Essien BE, Bonisch H, Schwaiger M, Gansbacher B, Weber WA. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. *The journal of gene medicine.* 2004;6(1):119-26.
47. Kohn DB, Gansbacher B. Letter to the editors of Nature from the American Society of Gene Therapy (ASGT) and the European Society of Gene Therapy (ESGT). *The journal of gene medicine.* 2003;5(7):641.
48. Gansbacher B. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT). *The journal of gene medicine.* 2003;5(3):261-2.
49. Bengel FM, Anton M, Richter T, Simoes MV, Haubner R, Henke J, Erhardt W, Reder S, Lehner T, Brandau W, Boekstegers P, Nekolla SG, Gansbacher B, Schwaiger M. Noninvasive imaging of transgene expression by use of positron emission tomography in a pig model of myocardial gene transfer. *Circulation.* 2003;108(17):2127-33.
50. Banke IJ, Arlt MJ, Pennington C, Kopitz C, Steinmetzer T, Schweinitz A, Gansbacher B, Quigley JP, Edwards DR, Sturzebecher J, Kruger A. Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors. *Biological chemistry.* 2003;384(10-11):1515-25.
51. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. *Gene therapy.* 2002;9(2):102-9.
52. Holm PS, Bergmann S, Jurchott K, Lage H, Brand K, Ladhoff A, Mantwill K, Curiel DT, Dobbstein M, Dietel M, Gansbacher B, Royer HD. YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. *The Journal of biological chemistry.* 2002;277(12):10427-34.
53. Gansbacher B. Policy statement on the social, ethical and public awareness issues in gene therapy. *The journal of gene medicine.* 2002;4(6):687-91.
54. Cohen-Haguenauer O, Rosenthal F, Gansbacher B, Bolhuis R, Dorsch-Hasler K, Eshhar Z, Gahrton G, Hokland P, Melani C, Rankin E, Thielemans K, Vile R, Zwierzina H, Cichutek K. Opinion

paper on the current status of the regulation of gene therapy in Europe. *Human gene therapy*. 2002;13(17):2085-110.

55. Haubner R, Anton M, Gertz S, Kruger A, Gansbacher B, Schwaiger M, Avril N. Quantification of transgene expression using herpes virus thymidine kinase and radioiodinated fiau. *Journal of Labelled Compounds and Radiopharmaceuticals* 44, 333-335, 2001

56. Arit M, Kopitz C, Pennington C, Watson KL, Krell HW, Bode W, Gansbacher B, Khokha R, Edwards DR, Kruger A. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. *Cancer research*. 2002;62(19):5543-50.

57. Kruger A, Soeltl R, Sopov I, Kopitz C, Arit M, Magdolen V, Harbeck N, Gansbacher B, Schmitt M. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. *Cancer research*. 2001;61(4):1272-5.

58. Brill T, Barba M, Breul J, Gansbacher B. [Gene therapy of prostate carcinoma]. *Der Internist*. 2001;42(10):1328-36, 39-40, 42-5.

59. Schendel DJ, Falk CS, Nossner E, Maget B, Kressenstein S, Urlinger S, Tampe R, Gansbacher B. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity. *Gene therapy*. 2000;7(11):950-9.

60. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Brenner M, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, Siegler HF, Barranger JA, Karlsson S, Kohn D, Galpin JE, Raffel C, Hesdorffer C, Ilan J, Cassileth P, O'Shaughnessy J, Kun LE, Das TK, Wong-Staal F, Sobol RE, Haubrich R, Szoln M, Rubin J, Sorcher EJ, Rosenblatt J, Walker R, Brigham K, Vogelzang N, Hersh E, Eck SL. Human gene marker/therapy clinical protocols. *Human gene therapy*. 2000;11(6):919-79.

61. Kruger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, Hantzopoulos PA, Graeff H, Gansbacher B, Schmitt M. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). *Cancer gene therapy*. 2000;7(2):292-9.

62. Haubner R, Avril N, Hantzopoulos PA, Gansbacher B, Schwaiger M. In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression: early kinetics of radiolabelled FIAU. *European journal of nuclear medicine*. 2000;27(3):283-91.

63. Bengel FM, Anton M, Avril N, Brill T, Nguyen N, Haubner R, Gleiter E, Gansbacher B, Schwaiger M. Uptake of radiolabeled 2'-fluoro-2'-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil in cardiac cells after adenoviral transfer of the herpesvirus thymidine kinase gene: the cellular basis for cardiac gene imaging. *Circulation*. 2000;102(9):948-50.

64. Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Graeff H, Gansbacher B, Kessler H, Bürgle M, Stürzebecher J, Sperl S, Magdolen V The urokinase plasminogen activator system as a novel target for tumour therapy *Fibrinolysis & Proteolysis* 14: 114-132, 2000

65. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Habib NA, et al. Human gene marker/therapy clinical protocols. *Human gene therapy*. 1999;10(18):3067-123.

66. Scott-Taylor TH, Gansbacher B, Sadelain M. Efficient retroviral infection of human cells utilising an adenoviral vector expressing the ecotropic receptor. *Advances in experimental medicine and biology*. 1998;451:423-30.

67. Scott-Taylor TH, Gallardo HF, Gansbacher B, Sadelain M. Adenovirus facilitated infection of human cells with ecotropic retrovirus. *Gene therapy*. 1998;5(5):621-9.

68. Roskrow MA, Gansbacher B. Recent developments in gene therapy for oncology and hematology. *Critical reviews in oncology/hematology*. 1998;28(3):139-51.

69. Daliani D, Ulmer RA, Jackow C, Pugh W, Gansbacher B, Cabanillas F, Duvic M, Sarris AH. Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. *Leukemia & lymphoma*. 1998;29(3-4):315-28.

70. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, et al. Human gene marker/therapy clinical protocols. *Human gene therapy*.

1997;8(18):2301-38.

71. Zier KS, Gansbacher B. IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. *Journal of molecular medicine (Berlin, Germany)*. 1996;74(3):127-34.

72. Zier KS, Gansbacher B. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells. *Eur J Cancer*. 1996;32A(8):1408-12.

73. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. *Immunology today*. 1996;17(1):39-45.

74. Wicke I, Gansbacher B. [Using the thymidine kinase gene in therapy of solid tumors]. *Der Internist*. 1996;37(4):369-73.

75. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cometta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Tiberghien P, et al. Human gene marker/therapy clinical protocols. *Human gene therapy*. 1996;7(18):2287-313.

76. Gansbacher B: Cytokine Gene Therapy. *The Mount Sinai Journal of Medicine* 61: 301-309, 1994

77. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cometta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Aebischer P, et al. Human gene marker/therapy clinical protocols. *Hum Gene Ther*. 1996 Aug 20;7(13):1621-47.

78. Hantzopoulos PA, Gansbacher B. [Gene therapy—current status and outlook]. *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin*. 1996;67(10):980-3.

79. Zier KS, Gansbacher B. The impact of gene therapy on T cell function in cancer. *Human gene therapy*. 1995;6(10):1259-64.

80. Tjuvajev JG, Stockhammer G, Desai R, Uehara H, Watanabe K, Gansbacher B, Blasberg RG. Imaging the expression of transfected genes in vivo. *Cancer research*. 1995;55(24):6126-32.

81. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. *Cancer research*. 1995;55(9):1902-10.

82. Salvadori S, Gansbacher B, Wernick I, Tirelli S, Zier K. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. *Human gene therapy*. 1995;6(10):1299-306.

83. Gansbacher B. Gentherapie, Hoffnungsträger für Millionen. *Chemie Heute* 9: 12-15. 1995

84. Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. *International journal of cancer*. 1995;61(2):253-60.

85. Guarini A, Gansbacher B, Cronin K, Fierro MT, Foa R. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. *Cytokines and molecular therapy*. 1995;1(1):57-64.

86. Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Sorrentino B, Velu T. European School of Oncology position paper. Gene therapy for the medical oncologist. *Eur J Cancer*. 1995;31A(9):1531-7.

87. Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russell S, Sorrentino B, Velu T. Vectors in cancer therapy: how will they deliver? *Cancer gene therapy*. 1995;2(4):291-7.

88. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L, Forni G: Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor α , Granulocyte-Macrophage Colony-stimulating Factor, and β -Interferon Gene or Admixed with Conventional Adjuvants. *Cancer Research* 54: 6022-6026, 1994.

89. Zier KS, Salvadori S, Cronin KC, Gansbacher B. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness. *Cancer gene therapy*. 1994;1(1):43-50.

90. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor

vaccines. *Cancer research*. 1994;54(7):1760-5.

91. Salvadori S, Gansbacher B, Zier K. Functional defects are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells. *Cancer gene therapy*. 1994;1(3):165-70.

92. Salvadori S, Gansbacher B, Pizzimenti AM, Zier KS. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. *J Immunol*. 1994;153(11):5176-82.

93. Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WD, Fair WR, Gilboa E. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. *Cancer research*. 1994;54(13):3516-20.

94. Rosenthal FM, Zier KS, Gansbacher B. Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity. *Current opinion in oncology*. 1994;6(6):611-5.

95. Rosenthal FM, Fruh R, Henschler R, Veelken H, Kulmburg P, Mackensen A, Gansbacher B, Mertelsmann R, Lindemann A. Cytokine therapy with gene-transfected cells: single injection of irradiated granulocyte-macrophage colony-stimulating factor-transduced cells accelerates hematopoietic recovery after cytotoxic chemotherapy in mice. *Blood*. 1994;84(9):2960-5.

96. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. *Blood*. 1994;83(5):1289-98.

97. Minasian LM, Gansbacher B. Second International Conference on Gene Therapy of Cancer. *Ann Oncol*. 1994;5(4):313-6.

98. Gansbacher B. Clinical application of immunostimulatory gene transfer. *Eur J Cancer*. 1994;30A(8):1187-90.

99. Gansbacher B. Cytokine gene therapy. *The Mount Sinai journal of medicine, New York*. 1994;61(4):301-9.

100. Foa R, Guarini A, Cignetti A, Cronin K, Rosenthal F, Gansbacher B. Cytokine gene therapy: a new strategy for the management of cancer patients. *Natural immunity*. 1994;13(2-3):65-75.

101. Cignetti A, Guarini A, Carbone A, Forni M, Cronin K, Forni G, Gansbacher B, Foa R. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. *Journal of the National Cancer Institute*. 1994;86(10):785-91.

102. Alosco T, Gansbacher B, Bankert R, Takita H, Petrelli N. Human lung tumor cell secretion of interleukin-2 for protection against tumor engraftment. *Ann Surg Oncol*. 1994;1(3):229-35.

103. Gansbacher B, Rosenthal FM, Zier K: Cytokine Gene Transfer into Tumor Cells and its Application to Human Cancer. *Clinical and Experimental Urology* 25: 106-111, 1993.

104. Tsai SC, Gansbacher B, Tait L, Miller FR, Heppner GH. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. *Journal of the National Cancer Institute*. 1993;85(7):546-53.

105. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. *J Immunol*. 1993;151(8):4209-20.

106. Schendel DJ, Gansbacher B. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. *Cancer research*. 1993;53(17):4020-5.

107. Salvadori S, Rosenthal FM, Cronin K, Gansbacher B, Zier KS. Tumor-bearing animals contain suppressed antitumor effectors the function of which can be unmasked by IL-2. *J Immunother*. 1993;14(3):216-20.

108. Porgador A, Gansbacher B, Bannerji R, Tzeheval E, Gilboa E, Feldman M, Eisenbach L. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. *International journal of cancer*. 1993;53(3):471-7.

109. Gansbacher B, Rosenthal FM, Zier K. Retroviral vector-mediated cytokine-gene transfer into tumor cells. *Cancer investigation*. 1993;11(3):345-54.

110. Chen LL, Gansbacher B, Gilboa E, Taetle R, Oval J, Hibbs MS, Huang CK, Clawson ML, Bilgrami S, Schlessinger J, et al. Retroviral gene transfer of epidermal growth factor receptor into HL60 cells results in a partial block of retinoic acid-induced granulocytic differentiation. *Cell Growth*

Differ. 1993;4(9):769-76.

111. Alosco T, Croy BA, Gansbacher B, Wang HQ, Rao U, Bankert R. Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells. *Cancer Immunol Immunother.* 1993;36(6):364-72.

112. Gansbacher B, Gilboa E: Lymphokine Combination Vectors: A New Tool for Tumor Vaccination in Leukemias/Lymphomas. *Haematology and Blood Transfusion* 34: 157-162, 1992.

113. Rosenthal F, Cronin K, Guarini R, Gansbacher B: IL-2 gene transfer into tumor cells and its application to human disease. *Progress in Immunology* 8: 361-367, 1992.

114. Gansbacher B, Houghton A, Livingston P, Minasian L, Rosenthal F, Gilboa E, Golde D, Oettgen H, Steffens T, Young Yang S, Wong G: Clinical Protocol: A Pilot Study of Immunization with HLA A2 Matched Allogeneic Melanoma Cells That Secrete Interleukin 2 in Patients with Metastatic Melanoma. *Human Gene Therapy* 3: 677-690, 1992.

115. Gansbacher B, Motzer R, Houghton A, Gilboa E, Bander N, Minasian L, Gastl G, Rosenthal F, Gilboa E, Scheinfeld J, Young Yang S, Wong G, Golde D, Reuter V, Livingston P, Bosl G, Nanus D, Fair WR: Clinical Protocol: A Pilot Study of Immunization with Interleukin 2 Secreting Allogeneic HLA A2 Matched Renal Cell Carcinoma Cells in Patients with Advanced Renal Cell Carcinoma. *Human Gene Therapy* 3: 691-703, 1992.

116. Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, Gee T, Straus D, Gansbacher B, Filippa D, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. *Blood.* 1992;79(5):1305-10.

117. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. *Cancer research.* 1992;52(22):6229-36.

118. Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gilboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. *Blood.* 1992;80(11):2817-25.

119. Foa R, Guarini A, Gansbacher B. IL2 treatment for cancer: from biology to gene therapy. *British journal of cancer.* 1992;66(6):992-8.

120. Caplen HS, Salvadori S, Gansbacher B, Zier KS. Post-transcriptional regulation of MHC class II expression in human T cells. *Cellular immunology.* 1992;139(1):98-107.

121. Taetle R, Oval J, Smedsrud M, Davis C, Gansbacher B. Analysis of granulocyte-macrophage colony-stimulating factor action in differentiating myeloid leukemia cells: treatment with DMSO may reveal a common pathway for growth factor gene regulation. *Experimental hematology.* 1991;19(3):213-20.

122. Oval J, Hershberg R, Gansbacher B, Gilboa E, Schlessinger J, Taetle R. Expression of functional epidermal growth factor receptors in a human hematopoietic cell line. *Cancer research.* 1991;51(1):150-6.

123. Krown SE, Gold JW, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, Brew BJ. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). *Annals of internal medicine.* 1990;112(11):812-21.

124. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. *The Journal of experimental medicine.* 1990;172(4):1217-24.

125. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. *Cancer research.* 1990;50(24):7820-5.

126. Zier K, Gansbacher B, Ikegaki N, Kennett R, Polakova K. Expression of HLA-DR mRNA in T cells following activation is early and can precede DNA synthesis. *Autoimmunity.* 1989;5(1-2):59-70.

127. Gansbacher B, Zier KS. HLA class II mRNA accumulation by activated human T cells following growth in conditioned medium. *Clinical and experimental immunology.* 1989;76(3):440-5.

128. Gansbacher B, Zier KS. Regulation of HLA-DR, DP, and DQ expression in activated T cells. *Cellular immunology.* 1988;117(1):22-34.

129. Gansbacher B, Levinson AI. Effect of PHA-activated T cells on B-cell differentiation. *Immunology.* 1986;58(2):191-6.

130. Zier KS, Gansbacher B, Scholz S, Albert E. Behavior of HLA-DR homozygous cells in MLC and PLT. *Transplantation proceedings.* 1981;13(1 Pt 2):1035-8.

131. Zier KS, Gansbacher B. Generation of discriminatory PL against HLA-D antigens not detected by serology. *Human immunology*. 1981;3(1):57-65.
132. Gansbacher B, Zier K, Albert ED. Priming against stimulator-derived alloantigens bound onto MLC-activated blasts. *Scandinavian journal of immunology*. 1980;12(2):159-64.
133. Albert ED, Scholz S, Zier K, Gansbacher B, Wank R, Schendel D. [Selection of donors for bone marrow transplantation in childhood leukemia (author's transl)]. *Monatsschr Kinderheilkd*. 1980;1

Projects

Memberships

ESGCT

HONORS AND AWARDS:

1. Travel Award to 41st Annual Meeting, American Academy of Allergy and Immunology, March 1985, New York, N.Y.
2. Young Investigator Award, American Academy of Allergy and Immunology, March 1985, New York, N.Y.
3. American Cancer Society Clinical Fellow, July 1987 - June 1988.
4. Visiting Professor, Targeted Genetics Institute, Seattle,
5. Visiting Professor, University of Illinois, Chicago
6. Cancer Research Institute F.M. Kirby Clinical Research Award for Cancer Immunology recipient 1993-1996
7. Degussa Foundation Prize, University of Frankfurt, November 1993.
8. Member European Task Force for Gene Therapy, 1993 -1996.
9. Chairman, European Task Force for Gene Therapy, 1995-1996.
10. Chairman of international review panel committee for German Government Agency for Research and Technology (BMFT) on: Application of Gene transfer technologies to human diseases. 1994 -1995
11. CaP CURE Research Award 1994
12. Member and Speaker of ASCO Educational Session of Gene Therapy 1995
13. Organizer (together with Prof. Hofschneider, MPI, Martinsried) of GAAC meeting on Gene Therapy, Kloster Seeon, Munich, Germany, October 1-3, 1995.
14. Visiting Professor, Kyushu University, Beppu Japan, January 1998
15. Board Member of European Working Group For Gene Therapy (EWGT) 1995-2004
16. Vice-President, European Working Group For Gene Therapy (EWGT), 1996-1999
17. President European Society of Gene Therapy (ESGT) 2000-2004
18. Member Kommission "Somatische Genterapie" Bundesärztekammer 1999-
19. Member Zentrale Kommission für Biologische Sicherheit (ZKBS) 1999-
20. Member Executive Committee of Eurenethy 1998-
21. Member expert panel EMEA 2002-2005
22. Chair of International Committee ASGT 2004-2006
23. Member Zentrale Ethikkommission der Bundesärztekammer 2004-
24. Member Executive Committee of Clinigene

Other Relevant Information